Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Conditions
Brief summary
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
Interventions
OTHERcycles of neoadjuvant therapy and duration of waiting for surgery
We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
Sponsors
West China Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed as primary lung cancer through cytology or histological examination; * ECOG score of 0 or 1; ③ 18 years old or above; * Received imaging examination, with a preliminary clinical staging of stage III; * Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available.
Exclusion criteria
* Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders; * Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| major pathological remission | one month | proportion of patients with no more than 10% residual viable tumor cells; patients who showed no viable tumor in the lung primary setting but lymph nodes show viable metastatic carcinoma were also classified as MPR |
| pathological complete remission | one month | proportion of patients without residual viable tumor cell on evaluation of resected lung cancer specimens including all sampled regional lymph nodes |
| survival time | 5 years | time since diagnosed with NSCLC |
Outcome results
None listed